245 related articles for article (PubMed ID: 20824026)
21. The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
Nabholtz JM; Gligorov J
Rev Recent Clin Trials; 2006 Sep; 1(3):237-49. PubMed ID: 18473976
[TBL] [Abstract][Full Text] [Related]
22. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
Mouridsen HT; Robert NJ
Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
[TBL] [Abstract][Full Text] [Related]
23. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
Howell A; Howell SJ; Clarke R; Anderson E
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
[TBL] [Abstract][Full Text] [Related]
24. The role of aromatase inhibitors in early breast cancer.
Chung CT; Carlson RW
Curr Treat Options Oncol; 2003 Apr; 4(2):133-40. PubMed ID: 12594939
[TBL] [Abstract][Full Text] [Related]
25. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
Markopoulos C
Surg Oncol; 2008 Aug; 17(2):113-28. PubMed ID: 18178077
[TBL] [Abstract][Full Text] [Related]
26. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
Mouridsen HT; Robert NJ
MedGenMed; 2005 Aug; 7(3):20. PubMed ID: 16369246
[TBL] [Abstract][Full Text] [Related]
27. Aromatase inhibitors in the management of early breast cancer.
Nabholtz JM
Eur J Surg Oncol; 2008 Nov; 34(11):1199-207. PubMed ID: 18359182
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane.
Macpherson IR; Lindsay C; Canney P
Breast Cancer (Dove Med Press); 2010 Oct; 2():59-70. PubMed ID: 24367167
[TBL] [Abstract][Full Text] [Related]
29. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
30. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C; Keam SJ
Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
[TBL] [Abstract][Full Text] [Related]
31. Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancer.
Nabholtz JM; Mouret-Reynier MA; Durando X; Van Praag I; Nayl B; Ferriere JP; Chollet P
Indian J Surg Oncol; 2010 Jan; 1(1):19-26. PubMed ID: 22930614
[TBL] [Abstract][Full Text] [Related]
32. Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer.
Nabholtz JM; Mouret-Reynier MA; Durando X; Van Praagh I; Al-Sukhun S; Ferriere JP; Chollet P
Expert Opin Pharmacother; 2009 Jun; 10(9):1435-47. PubMed ID: 19445563
[TBL] [Abstract][Full Text] [Related]
33. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
Ingle JN
Clin Cancer Res; 2005 Jan; 11(2 Pt 2):900s-5s. PubMed ID: 15701884
[TBL] [Abstract][Full Text] [Related]
34. Reducing the risk of late recurrence in hormone-responsive breast cancer.
Cufer T
Ann Oncol; 2007 Sep; 18 Suppl 8():viii18-25. PubMed ID: 17890210
[TBL] [Abstract][Full Text] [Related]
35. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
Perez EA
Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
[TBL] [Abstract][Full Text] [Related]
36. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
[TBL] [Abstract][Full Text] [Related]
37. Letrozole: a review of its use in postmenopausal women with breast cancer.
Simpson D; Curran MP; Perry CM
Drugs; 2004; 64(11):1213-30. PubMed ID: 15161328
[TBL] [Abstract][Full Text] [Related]
38. Safety of aromatase inhibitors in the adjuvant setting.
Perez EA
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):75-89. PubMed ID: 17912638
[TBL] [Abstract][Full Text] [Related]
39. Optimal treatment strategies in hormone-responsive early breast cancer: the role of aromatase inhibitors.
Untch M; Jackisch C
Onkologie; 2007 Feb; 30(1-2):55-64. PubMed ID: 17264527
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.
Carlson RW; Hudis CA; Pritchard KI; ; ;
J Natl Compr Canc Netw; 2006 Nov; 4(10):971-9. PubMed ID: 17112447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
